Medical Stock Spotlight – market’s stampede into stocks that could, even remotely, benefit from the coronavirus outbreak

Thinly traded nano cap Cleveland BioLabs Inc. (Nasdaq:CBLI) led advancing issues, skyrocketing 220% over the week to $4.23 as yet another company is caught up in the market’s stampede into… Read more »

Trump changes Medicaid

      No Comments on Trump changes Medicaid

The News: The Trump administration on Thursday (February 6, 2020) said it will experiment with allowing state Medicaid programs to limit health benefits and prescription drug coverage for some patients… Read more »

As deaths surge, WHO says too early to declare coronavirus peaking in China, elsewhere.

The News: An American citizen has died in Wuhan, China, from the coronavirus epidemic, with the death toll edging closer to the total from SARS (severe acute respiratory syndrome, circa… Read more »

2020’s health-sector IPO action is blasting off with the pricing of a China-based biggie and a bunch of new filings.

The US health-sector IPO action continues to scramble for public funding leadership. And it’s beginning with a Chinese company that raked in over $100 million. Let’s check out the action… Read more »

Drug regulators in China, US and Europe out of the gates in 2020 with a whole month’s worth of action.

Slowly at first, then accelerating recently in its domestic and global footprint in drug research and regulation, China and its National Medical Products Administration (NMPA) has been on a tear…. Read more »

Health-sector IPO action picks up where 2019 left off with new SEC filings signaling high hopes for cash still parked on the sidelines.

Despite clashes over trade sanctions pending resolution with China and threats of war with Iran escalating to nerve-wracking heights, confidence in the US market for health-sector initial public offerings apparently… Read more »

China’s BeiGene gets nod from FDA for lymphoma med; significance extends further than just a win for one Chinese biotech.

The News: The US Food and Drug Administration has given the green light to market a blood cancer drug from Beijing-based BeiGene Ltd., paving the way for American patients to access a Chinese… Read more »

FDA panel unanimously backs use of Amarin’s fish-oil heart drug; action could produce gigantic profit haul.

The News: Government health experts recently recommended broader use of a prescription-strength fish oil drug to help many more patients at risk for heart attack, stroke and related health problems…. Read more »

In a seeming role-reversal, FDA steps up action over Thanksgiving week while EMA goes on holiday.

Although usually thought of as a well-deserved respite from governmental rulings, the US Food and Drug Administration seized on Thanksgiving week as a demonstration of its zeal to pump out… Read more »